Novo Nordisk establishes type 1 diabetes R&D center in Seattle

Novo NordiskNovo Nordisk will establish a type 1 diabetes R&D center in Seattle, US. The new center will combine Novo Nordisk's history of innovation and leadership in diabetes treatment with the company's growing expertise in immunotherapy.

The unique concept behind the new center is to pursue a translational research approach characterised by combining basic research and early proof-of-concept trials under one umbrella. This will give the new center the necessary scientific foundation to move early-stage discovery projects rapidly from animal models into small clinical exploratory trials in type 1 diabetes.

In the past decade, type 2 diabetes has been the main focus among diabetes researchers and pharmaceutical companies because of the dramatic rise in the number of people living with the disease. Type 1 diabetes is a different disease that requires life-saving treatment with insulin. Unfortunately, there has been a lack of major scientific progress in this area in recent years.

"Novo Nordisk has been passionate about helping people fight diabetes since the company was founded, and it is our mission to take type 1 diabetes research to the next level. With the new type 1 diabetes R&D center, we hope to accelerate the process of finding new, innovative ways of treating people with this disease. Our vision is to prevent, treat and ultimately cure diabetes," says Mads Krogsgaard Thomsen, executive vice president and chief science officer at Novo Nordisk.

Matthias von Herrath, MD, has accepted the position as head of the new diabetes research centre. He is a world-renowned researcher in auto-immune diseases and he received the American Diabetes Association Outstanding Achievement Award in 2008.

"My dream has always been to see some of the treatments that my and other research teams have tested in animal models translated into better treatments for type 1 diabetes. As head of the research center, I hope to pursue this dream, while also forging new public–private collaborations within this field," says Matthias von Herrath.

Matthias von Herrath currently holds the position as director of the Center for Type 1 Diabetes Research at La Jolla Institute for Allergy and Immunology. He has been with the institute since 2001 and will continue to hold a part-time faculty position there. Dr von Herrath also serves as president of both the Immunology of Diabetes Society (IDS) and the Clinical Immunology Society (CIS).

The Novo Nordisk Type 1 Diabetes R&D Center is planned to open this summer with about 20 researchers supported by corporate functions in US and Denmark. The new centre will be located on the same premises as the Novo Nordisk Inflammation Research Center in Seattle in order to foster natural research synergies between the two sites.

Globally, about 6,000 employees worldwide are involved in research and development activities in Novo Nordisk. Novo Nordisk has research facilities in Måløv (Denmark), Beijing and Seattle.

About diabetes
There are two kinds of diabetes: type 1 and type 2. In International Diabetes Federation’s 5th edition of the Diabetes Atlas it is estimated that 366 million people were living with diabetes in 2011. Type 1 diabetes accounts for 5–10% of the total worldwide population with diabetes.

Type 1 diabetes is sometimes called insulin-dependent, immune-mediated or juvenile-onset diabetes. It is caused by an auto-immune reaction where the body’s defence system attacks its own insulin-producing cells. The reason why this occurs is not fully understood. People with type 1 diabetes produce very little or no insulin. The disease can affect people of any age, but usually occurs in children or young adults. People with this form of diabetes need injections of insulin every day in order to control the levels of glucose in their blood. If people with type 1 diabetes do not have access to insulin, they will die.

Most Popular Now

In wine, there's health: Low levels of alcohol goo…

While a couple of glasses of wine can help clear the mind after a busy day, new research shows that it may actually help clean the mind as well. The new study, which appe...

Sanofi to acquire Ablynx for €3.9 Billion

Sanofi and Ablynx, a biopharmaceutical company engaged in the discovery and development of Nanobodies®, entered into a definitive agreement under which Sanofi will offer ...

Repurposed drug found to be effective against Zika…

In both cell cultures and mouse models, a drug used to treat Hepatitis C effectively protected and rescued neural cells infected by the Zika virus - and blocked transmiss...

Interim publications of randomized trials make new…

Early results from randomized trials are sometimes published before the trial is completed. The results of such interim publications may generate a great deal of interest...

Drug trial protocol redactions by industry sponsor…

New research published by the Journal of the Royal Society of Medicine exposes the extent of redactions in protocols for industry-sponsored randomised drug trials. Trial ...

Advanced Accelerator Applications receives FDA ap…

Novartis AG (NYSE: NVS) announced that Advanced Accelerator Applications, a subsidiary of Novartis Groupe S.A., has received US Food and Drug Administration (FDA) approva...

Blood vessel-on-a-chips show anti-cancer drug effe…

Researchers at the Institute of Industrial Science (IIS), the University of Tokyo, CNRS and INSERM, report a new organ-on-a-chip technology for the study of blood vessel ...

Guidelines extended to improve the use of feedback…

Researchers have recommended changes to international guidelines used in the development of clinical trials in an effort to gain information about the impact of the treat...

Brilinta significantly reduces CV events and coron…

AstraZeneca today announced results from a new sub-analysis of the Phase III PEGASUS-TIMI 54 trial, demonstrating a risk reduction of 19% in MACE (the composite of CV dea...

Roche reports good results in 2017

In 2017, Group sales rose 5% to CHF 53.3 billion. Core operating profit grew 3% and Core EPS increased 5%, reflecting the good underlying business performance. On an IFRS...

FDA approves new treatment for certain digestive t…

The U.S. Food and Drug Administration today approved Lutathera (lutetium Lu 177 dotatate) for the treatment of a type of cancer that affects the pancreas or gastrointesti...

How old antibiotic compounds could become tomorrow…

As the fight against drug-resistant infections continues, University of Leeds scientists are looking back at previously discarded chemical compounds, to see if any could ...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]